GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (OTCPK:KDEVF) » Definitions » Cash-to-Debt

Karolinska Development AB (Karolinska Development AB) Cash-to-Debt : 27.63 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Karolinska Development AB Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Karolinska Development AB's cash to debt ratio for the quarter that ended in Mar. 2024 was 27.63.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Karolinska Development AB could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Karolinska Development AB's Cash-to-Debt or its related term are showing as below:

KDEVF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.16   Med: 0.96   Max: No Debt
Current: 27.6

During the past 13 years, Karolinska Development AB's highest Cash to Debt Ratio was No Debt. The lowest was 0.16. And the median was 0.96.

KDEVF's Cash-to-Debt is ranked better than
67.58% of 1539 companies
in the Biotechnology industry
Industry Median: 6.51 vs KDEVF: 27.60

Karolinska Development AB Cash-to-Debt Historical Data

The historical data trend for Karolinska Development AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Karolinska Development AB Cash-to-Debt Chart

Karolinska Development AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.27 1.53 0.74 271.63 31.19

Karolinska Development AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 321.10 432.50 552.74 31.19 27.63

Competitive Comparison of Karolinska Development AB's Cash-to-Debt

For the Biotechnology subindustry, Karolinska Development AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Karolinska Development AB's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karolinska Development AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Karolinska Development AB's Cash-to-Debt falls into.


Karolinska Development AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Karolinska Development AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=9.326 / (0.299 + 0)
=31.19

Karolinska Development AB's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=7.514 / (0.272 + 0)
=27.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karolinska Development AB  (OTCPK:KDEVF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Karolinska Development AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Karolinska Development AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Karolinska Development AB (Karolinska Development AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (OTCPK:KDEVF) » Definitions » Cash-to-Debt
Comparable Companies
OSTO:MVIR OSTO:NICA OSTO:INDEX OSTO:IVACC OSTO:IRLAB A OSTO:IMMU OSTO:SANION OSTO:GUARD OSTO:INIT OSTO:KAN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
KDEV:Sweden 2I9:Germany
Address
TomtebodavAgen 23 A, Solna, SWE, SE-171 65
Website
https://www.karolinskadevelopment.com
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.